While relatively little is known about the intricacies of mTORC2 signaling in HNSCC, there is substantial interest in targeting the PI3K pathway (e.g., via targeted inhibition of PI3K, Akt, or mTORC1). The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.